Compare Sanofi SA (SNY) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs TeraWulf Inc — how do they compare? Sanofi SA trades at $43.61 (market cap $104.30B), while TeraWulf Inc trades at $17.37 (market cap $8.35B). The key difference: Sanofi SA is far larger — about 12.5× TeraWulf Inc's market cap, and Sanofi SA pays a 5.55% dividend while TeraWulf Inc pays none. Which is the better fit depends on your goals.
| SNY | WULF | |
|---|---|---|
Market Cap | $104.30B | $8.35B |
Sector | Health | Technology |
52-Week High | $52.34 | $28.98 |
52-Week Low | $41.33 | $5.24 |
Enterprise Value | $124.19B | $10.97B |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
WULF trades at $17.04, up 5.19% on the day amid a broader neocloud infrastructure rally. The stock shows bearish technical signals with 17 sell signals versus 2 buys, while fundamentals reveal significant challenges with a -1,179.94% net income margin and consistent earnings misses. Recent Q2 2026 results showed a $0.37 per share loss versus $0.20 expected, though revenue beat estimates. The company is expanding its high-performance computing capacity with 102 MW operational and 336 MW under construction, supported by a major Anthropic leasing agreement.
Despite unanimous analyst buy ratings and a $38 consensus price target representing 123% upside, WULF faces substantial execution risks and profitability concerns. The transition to AI infrastructure offers long-term potential, but near-term losses and high capital requirements create volatility. Investors should weigh the significant growth opportunity against persistent negative cash flow and competitive pressures in the evolving data center market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
